Biotech Values

[DewDiligence]

IDX899 update from IDIX CC:

The 400mg dosing cohort has now been completed and the reduction in viral load was in the 1.5-2-log range, which is about as good as one can get in a short HIV study (#msg-27349650).

Because the requisite potency was seen at 400mg, dosing in the 200mg cohort has begun. If 200mg shows sufficient potency, a 100mg dose may also be tested.

IDIX’s reasons for testing lower and lower doses are set forth in #msg-26800695.

There have been zero patient discontinuations to date in any of the dosing cohorts.